TDOC
Teladoc Health, Inc.
$7.08
+0.43%
$1.3B
No data for this timeframe.
Vol
Market Cap$1.3B
Cap SizeSmall Cap
Analyst ConsensusHold (36%)
Inst. Holders8 funds
Inst. Value$250.4M
Inst. Activity1 buys / 3 sells
Insider Activity0B / 14S
Insider Net $-$1.2M
Reddit Sentiment50° Neutral
SEC Reports8
Press Releases1
Exchange NYSE·Sector Services-Offices & Clinics of Doctors of Medicine·Inc. DE·CIK 0001477449·Prev Close $7.05
Recent Activity
Jun 3, 2026
Insider
Rodrigues Fernando M. sold 9,572 shares
President of BetterHelp @ $7.40 ($70.8K)
Jun 2, 2026
SEC
Charles Divita III, a director of Teladoc Health, filed a Form 144 notice of intent to sell 19,132 shares of common stoc
144 — Impact 2/10
Jun 2, 2026
SEC
Adam Vandervoort, an officer of Teladoc Health, filed a Form 144 notice of intent to sell 7,906 shares of common stock,
144 — Impact 2/10
Jun 2, 2026
Insider
Catapano Joseph Ronald sold 284 shares
Chief Accounting Officer @ $7.63 ($2.2K)
Jun 2, 2026
Insider
Bliss Kelly sold 7,679 shares
President, U.S. Group Health @ $7.63 ($58.6K)
Apr 15, 2026
SEC
Teladoc Health announced it will release Q1 2026 earnings on April 29, 2026, after market close, with a conference call
PRESS-RELEASE — Impact 3/10
Inst.
MORGAN STANLEY — TRIM
1,675,282 shares ($11.7M)
Inst.
FMR LLC — ADD
736,726 shares ($5.2M)
Price Targets
$7.24
+4.4% upside
Hold
Current $6.93
Low $5.00
Median $7.00
High $10.00
21 analysts
$5.00
$10.00
Analyst Ratings
4Strong Buy
8Buy
21Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Apr 8, 2026 | Evercore ISI Group | MAINTAIN | In-Line → In-Line |
| Mar 26, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| Mar 13, 2026 | JP Morgan | MAINTAIN | Neutral → Neutral |
| Mar 10, 2026 | Deutsche Bank | UPGRADE | Hold → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▼ -6.0% | $-0.24 — $-0.23 | -61% YoY | 3 |
| Next Q | $-0.17 ▲ +7.1% | $-0.20 — $-0.16 | 8% YoY | 3 |
| Current FY | $-0.79 ▲ +16.2% | $-0.89 — $-0.61 | -20% YoY | 4 |
| Next FY | $-0.65 ▲ +30.6% | $-0.78 — $-0.55 | 18% YoY | 4 |
Latest Reports
NEUTRAL
144
2/10
Charles Divita III, a director of Teladoc Health, filed a Form 144 notice of intent to sell 19,132 shares of common stoc
Jun 2, 2026
NEUTRAL
144
2/10
Adam Vandervoort, an officer of Teladoc Health, filed a Form 144 notice of intent to sell 7,906 shares of common stock,
Jun 2, 2026
NEUTRAL
Press
3/10
Teladoc Health appointed Susan Salka, former CEO of AMN Healthcare, to its board of directors, effective immediately. Th
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $150.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $55.8M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $17.8M | NEW |
| MORGAN STANLEY | $11.7M | TRIM |
| FMR LLC | $5.2M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Rodrigues Fernando | SELL | $70.8K |
| Jun 2, 2026 | Catapano Joseph | SELL | $2.2K |
| Jun 2, 2026 | Bliss Kelly | SELL | $58.6K |
| Jun 2, 2026 | Rodrigues Fernando | SELL | $43.3K |
| Jun 2, 2026 | DIVITA CHARLES | SELL | $145.9K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $250.4M total value (35,773,921 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, CHARLES. Net selling activity: 3 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 21,483,707 | $150.4M | 60.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 7,978,142 | $55.8M | 22.3% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,546,622 | $17.8M | 7.1% | NEW |
| 4 | MORGAN STANLEY | 1,675,282 | $11.7M | 4.7% | TRIM -53.5% |
| 5 | FMR LLC | 736,726 | $5.2M | 2.1% | ADD +26.8% |
| 6 | TWO SIGMA INVESTMENTS, LP | 677,555 | $4.7M | 1.9% | TRIM -40.1% |
| 7 | BANK OF AMERICA CORP /DE/ | 409,177 | $2.9M | 1.1% | TRIM -38.2% |
| 8 | WELLS FARGO & COMPANY/MN | 266,710 | $1.9M | 0.7% | ADD +53.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 3,600,271 | 1,675,282 | -53.5% | $11.7M | 2025-Q4 |
| FMR LLC | ADD | 580,913 | 736,726 | +26.8% | $5.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,131,668 | 677,555 | -40.1% | $4.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 661,602 | 409,177 | -38.2% | $2.9M | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,955,722 | 3,600,271 | +84.1% | $27.8M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 2,185,390 | 1,131,668 | -48.2% | $8.7M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,585,045 | 661,602 | -58.3% | $5.1M | 2025-Q3 |
| FMR LLC | ADD | 298,249 | 580,913 | +94.8% | $4.5M | 2025-Q3 |
| NORGES BANK | EXIT | 178,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | TRIM | 2,845,884 | 1,955,722 | -31.3% | $17.0M | 2025-Q2 |
| UBS Group AG | TRIM | 1,720,336 | 1,207,037 | -29.8% | $10.5M | 2025-Q2 |
| FMR LLC | DOUBLED | 93,959 | 298,249 | +217.4% | $2.6M | 2025-Q2 |
| NORGES BANK | NEW | — | 178,000 | — | $1.6M | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 2,468,102 | 3,427,059 | +38.9% | $27.3M | 2025-Q1 |
| MORGAN STANLEY | ADD | 2,168,228 | 2,845,884 | +31.3% | $22.7M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 127,521 | 195,167 | +53.0% | $1.6M | 2025-Q1 |
| FMR LLC | TRIM | 253,577 | 93,959 | -62.9% | $747.9K | 2025-Q1 |
| NORGES BANK | EXIT | 178,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 1,953,212 | 2,468,102 | +26.4% | $22.4M | 2024-Q4 |
| NORGES BANK | NEW | — | 178,000 | — | $1.6M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 2,059,185 | — | $18.9M | 2024-Q3 |
13 unique insiders with 14 transactions. Net insider value: -$1.2M ($0.00 bought, $1.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Rodrigues Fernando M. | President of BetterHelp | SELL | 9,572 | $7.40 | $70.8K |
| Jun 2, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | SELL | 284 | $7.63 | $2.2K |
| Jun 2, 2026 | Bliss Kelly | President, U.S. Group Health | SELL | 7,679 | $7.63 | $58.6K |
| Jun 2, 2026 | Rodrigues Fernando M. | President of BetterHelp | SELL | 5,677 | $7.63 | $43.3K |
| Jun 2, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | SELL | 19,132 | $7.63 | $145.9K |
| Jun 2, 2026 | Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | SELL | 7,906 | $7.63 | $60.3K |
| Jun 2, 2026 | Nueno Carlos | President, International | SELL | 6,196 | $7.63 | $47.3K |
| Jun 1, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | M | 39 | $0.00 | $0.00 |
| Jun 1, 2026 | Bliss Kelly | President, U.S. Group Health | M | 1,300 | $0.00 | $0.00 |
| Jun 1, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | M | 833 | $0.00 | $0.00 |
| Jun 1, 2026 | Bliss Kelly | President, U.S. Group Health | M | 4,858 | $0.00 | $0.00 |
| Jun 1, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | M | 39 | $0.00 | $0.00 |
| Jun 1, 2026 | Bliss Kelly | President, U.S. Group Health | M | 1,300 | $0.00 | $0.00 |
| Jun 1, 2026 | Rodrigues Fernando M. | President of BetterHelp | M | 5,491 | $0.00 | $0.00 |
| Jun 1, 2026 | Rodrigues Fernando M. | President of BetterHelp | M | 5,491 | $0.00 | $0.00 |
| Jun 1, 2026 | Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | M | 426 | $0.00 | $0.00 |
| Jun 1, 2026 | Nueno Carlos | President, International | M | 4,556 | $0.00 | $0.00 |
| Jun 1, 2026 | Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | M | 426 | $0.00 | $0.00 |
| Jun 1, 2026 | Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | M | 5,350 | $0.00 | $0.00 |
| Jun 1, 2026 | Nueno Carlos | President, International | M | 4,556 | $0.00 | $0.00 |
| Jun 1, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | M | 1,966 | $0.00 | $0.00 |
| Jun 1, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | M | 1,966 | $0.00 | $0.00 |
| Jun 1, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | M | 42,276 | $0.00 | $0.00 |
| May 21, 2026 | Jacobson Catherine | Director | A | 30,441 | $0.00 | $0.00 |
| May 21, 2026 | SHEDLARZ DAVID L | Director | A | 30,441 | $0.00 | $0.00 |
| May 21, 2026 | Fenwick Sandra L | Director | A | 30,441 | $0.00 | $0.00 |
| May 21, 2026 | Smith Mark Douglas | Director | A | 30,441 | $0.00 | $0.00 |
| May 21, 2026 | SNOW DAVID B JR | Director | A | 30,441 | $0.00 | $0.00 |
| May 21, 2026 | Paulus Kenneth H | Director | A | 30,441 | $0.00 | $0.00 |
| May 20, 2026 | SHEDLARZ DAVID L | Director | M | 29,986 | $0.00 | $0.00 |
| May 20, 2026 | SHEDLARZ DAVID L | Director | M | 28,986 | $0.00 | $0.00 |
| May 20, 2026 | Jacobson Catherine | Director | M | 28,986 | $0.00 | $0.00 |
| May 20, 2026 | SNOW DAVID B JR | Director | M | 28,986 | $0.00 | $0.00 |
| May 20, 2026 | SNOW DAVID B JR | Director | M | 28,986 | $0.00 | $0.00 |
| May 20, 2026 | Jacobson Catherine | Director | M | 28,986 | $0.00 | $0.00 |
| Apr 2, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | SELL | 675 | $5.11 | $3.5K |
| Apr 1, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | M | 2,083 | $0.00 | $0.00 |
| Apr 1, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | M | 2,083 | $0.00 | $0.00 |
| Mar 30, 2026 | SALKA SUSAN R | Director | A | 48,638 | $0.00 | $0.00 |
| Mar 11, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | SELL | 27,731 | $5.49 | $152.2K |
| Mar 10, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | M | 39,160 | $0.00 | $0.00 |
| Mar 10, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | M | 39,160 | $0.00 | $0.00 |
| Mar 10, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | A | 43,703 | $0.00 | $0.00 |
| Mar 10, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | M | 25,493 | $0.00 | $0.00 |
| Mar 2, 2026 | Nueno Carlos | President, International | SELL | 20,165 | $5.12 | $103.2K |
| Mar 2, 2026 | Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | SELL | 27,083 | $5.12 | $138.6K |
| Mar 2, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | SELL | 50,145 | $5.12 | $256.6K |
| Mar 2, 2026 | Bliss Kelly | President, U.S. Group Health | SELL | 26,647 | $5.12 | $136.4K |
| Mar 2, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | SELL | 1,333 | $5.12 | $6.8K |
| Mar 1, 2026 | Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | A | 181,661 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 5 neutral. Avg impact: 4.0/10.
NEUTRAL
144
2/10
Charles Divita III, a director of Teladoc Health, filed a Form 144 notice of intent to sell 19,132 s
Jun 2, 2026
NEUTRAL
144
2/10
Adam Vandervoort, an officer of Teladoc Health, filed a Form 144 notice of intent to sell 7,906 shar
Jun 2, 2026
NEUTRAL
PRESS-RELEASE
3/10
Teladoc Health announced it will release Q1 2026 earnings on April 29, 2026, after market close, wit
Apr 15, 2026
NEUTRAL
DEFA14A
3/10
Teladoc Health is holding its 2026 annual meeting to elect nine directors, approve executive compens
Apr 7, 2026
NEUTRAL
3
2/10
Susan R. Salka, a reporting owner at Teladoc Health, filed a Form 3 to report her initial beneficial
Apr 1, 2026
BEARISH
CLUSTER
7/10
Multiple high-level executives at Teladoc Health, including CEO Charles Divita and other C-suite lea
Mar 3, 2026
BEARISH
CLUSTER
7/10
Three top executives at Teladoc Health — including CEO Charles Divita and the Chief Legal Officer —
Mar 3, 2026
MIXED
8-K
6/10
Teladoc Health reported flat Q4 revenue of $642.3 million (0% YoY) and full-year 2025 revenue down 2
Feb 26, 2026
Current analyst consensus: Sell (36% buy). Based on 33 analysts: 4 strong buy, 8 buy, 21 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.24 mean target
+4.4% upside
Hold (2.50)
$5.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $6.93 |
| Target Low | $5.00 |
| Target Mean | $7.24 |
| Target Median | $7.00 |
| Target High | $10.00 |
| # Analysts | 21 |
| Recommendation | Hold (2.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.24 | $-0.23 | -60.7% | -6.0% | 0↑ 2↓ | $0.6B | -2.6% | 3 |
| Next Q 2026-09-30 |
$-0.17 | $-0.20 | $-0.16 | 7.7% | +7.1% | 1↑ 0↓ | $0.6B | 0.4% | 3 |
| Current FY 2026-12-31 |
$-0.79 | $-0.89 | $-0.61 | -20.0% | +16.2% | 2↑ 1↓ | $2.5B | -1.0% | 4 |
| Next FY 2027-12-31 |
$-0.65 | $-0.78 | $-0.55 | 17.8% | +30.6% | 2↑ 0↓ | $2.5B | 1.3% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.237 | |
| 7d ago | $-0.237 | |
| 30d ago | $-0.223 | -0.013 |
| 60d ago | $-0.223 | -0.013 |
| 90d ago | $-0.223 | -0.013 |
13 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Apr 8, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Mar 26, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 13, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Mar 10, 2026 | Deutsche Bank | UPGRADE | Hold | Buy |
| Mar 3, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 3, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 26, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Leerink Partners | MAINTAIN | Market Perform | Market Perform |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| Feb 26, 2026 | BMO Capital | MAINTAIN | Market Perform | Market Perform |
| Feb 26, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Feb 26, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 26, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Feb 26, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Jan 9, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 8 | 21 | 0 | 0 | 36% | |
| May 1, 2026 | 4 | 8 | 21 | 0 | 0 | 36% | |
| Apr 1, 2026 | 4 | 8 | 21 | 0 | 0 | 36% | |
| Mar 1, 2026 | 4 | 7 | 23 | 0 | 0 | 32% | |
| Feb 1, 2026 | 3 | 7 | 24 | 0 | 0 | 29% | |
| Jan 1, 2026 | 3 | 7 | 24 | 0 | 0 | 29% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 22, 2026
short_volume
Short Volume: TDOC — 55.7% short (0.5M / 0.9M)
Short: 484,602 | Exempt: 949 | TRF Vol: 869,569 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: TDOC — 63.1% short (0.7M / 1.2M)
Short: 741,953 | Exempt: 2,449 | TRF Vol: 1,175,236 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: TDOC — 60.7% short (0.7M / 1.1M)
Short: 671,862 | Exempt: 2,435 | TRF Vol: 1,106,376 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: TDOC — 57.4% short (1.6M / 2.8M)
Short: 1,582,775 | Exempt: 17,664 | TRF Vol: 2,755,169 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
earnings
Teladoc Health Reports First Quarter 2026 Results
<p align="left">NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported fi
Apr 29, 2026
short_volume
Short Volume: TDOC — 66.0% short (1.5M / 2.3M)
Short: 1,495,109 | Exempt: 14 | TRF Vol: 2,265,633 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
earnings_calendar
TDOC Q1 2026 Earnings After Market Close — 2026-04-29
Apr 23, 2026
short_volume
Short Volume: TDOC — 55.9% short (1.2M / 2.2M)
Short: 1,218,008 | Exempt: 207 | TRF Vol: 2,177,378 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
earnings
Teladoc Health to Announce First Quarter 2026 Financial Results
<p>NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release
Mar 31, 2026
short_volume
Short Volume: TDOC — 57.1% short (1.8M / 3.1M)
Short: 1,776,991 | Exempt: 4,893 | TRF Vol: 3,109,911 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
leadership
Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
<p>NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of S
Mar 26, 2026
short_volume
Short Volume: TDOC — 78.9% short (1.7M / 2.2M)
Short: 1,743,233 | Exempt: 3,828 | TRF Vol: 2,210,285 | Short Ratio: 78.9% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
short_volume
Short Volume: TDOC — 67.2% short (1.3M / 1.9M)
Short: 1,293,961 | Exempt: 8,809 | TRF Vol: 1,924,156 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: TDOC — 56.0% short (1.0M / 1.9M)
Short: 1,036,832 | Exempt: 2,670 | TRF Vol: 1,850,517 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Mar 4, 2026
other
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
<p>NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued